PoLoPo

**Product and the concrete problem it solves.** PoLoPo is tackling a supply problem that sits underneath both alternative protein and food resilience: many food manufacturers want functional proteins with familiar taste, texture, and formulation behavior, but conventional animal agriculture is resource-intensive and exposed to disease, climate, land, water, and geopolitical shocks. Precision fermentation can produce animal-identical ingredients, yet it requires fermentation capacity, feedstocks, downstream purification, and new manufacturing economics. PoLoPo's answer is a molecular-farming platform in which the crop itself produces the target protein. The company initially pursued ovalbumin, the main functional protein in egg white, and more recently positioned protein-rich potatoes as an ingredient for high-protein potato chips. This is a concrete product strategy rather than a general promise to make food in plants: the potato remains a familiar agricultural crop, the protein is accumulated in the tuber, and the output can be processed into an ingredient or a snack format. The current wedge is especially practical because PoLoPo says brands can introduce high-protein chips without adding powders, changing processing lines, or asking consumers to accept a visibly unfamiliar product.

**Core technology and how it actually works.** PoLoPo calls its platform SuperAA. The public description is that the company uses directed metabolic engineering to increase protein production in potato plants, making the plant a biofactory rather than merely a source of starch. In its original ingredient model, genetically engineered potato varieties are designed to produce animal-identical proteins such as ovalbumin inside the tuber; the harvested potatoes can then be processed, and the target protein extracted and dried for use in food formulations. In its snack-oriented model, the same platform is used to increase the potato's native protein content, with the company claiming up to three times more protein than conventional tubers in a chip format. The technical chain therefore has several linked steps: select or engineer a potato genotype, express and accumulate the target protein in the tuber, grow the crop under controlled and field conditions, harvest enough biomass, separate and stabilize the functional protein, and demonstrate that the resulting ingredient behaves acceptably in a customer's recipe. Public sources do not establish the exact genetic constructs, expression yields, purification recovery, allergen profile, or cost per kilogram. Those unknowns matter because a high protein signal in a plant is not the same as a commercially useful, consistent, regulatorily approvable ingredient.

**Market, customers, and go-to-market.** PoLoPo is a B2B ingredient and agricultural-biotechnology company, not a consumer packaged-goods brand with a disclosed retail business. Its original market was manufacturers seeking animal-based proteins without chickens or livestock, including food, dairy-alternative, meat-alternative, and potentially nutraceutical applications. The current public go-to-market emphasizes snack brands and potato processors: PoLoPo supplies or licenses improved potato varieties and works with manufacturers to create high-protein chips that preserve familiar crunch and flavor. The appeal is a drop-in processing proposition. If the protein is grown in the potato instead of added as a powder after harvest, a producer may avoid a new ingredient-handling step and keep existing frying, seasoning, and packaging equipment. PoLoPo's website explicitly invites partnerships with brands developing high-protein snacks and clean-label products, and PotatoPro reports that a pilot program was underway with additional partners invited. No customer names, signed supply agreements, volumes, recurring revenue, or commercial launch dates are publicly confirmed. The likely route to market is therefore a partnership model combining seed or variety development, field trials, ingredient samples, regulatory work, and co-development with large food manufacturers.

**Traction, funding, and third-party validation.** PoLoPo has a meaningful technical progression record for a small early-stage company. Public coverage says it moved from greenhouse work to outdoor field cultivation of protein-producing potatoes in early 2025, expanding the quantity of material available for samples and testing. New Tech Foods described an anticipated increase from tens of kilograms to as much as three tons of harvested material, although that is a planned or expected scale figure rather than an independently audited production result. The company raised approximately $1.75 million in a pre-seed round led by FoodLabs, with participation from CPT Capital, Siddhi Capital, Plug and Play, Milk & Honey Ventures, and HackCapital; Startup Nation Finder later reports approximately $2.3 million including subsequent support or grants. PoLoPo also received €20,000 in EIT Food technology-validation funding and was reported as a winner of a 2025 women-entrepreneur impact competition. These are useful ecosystem signals, but they do not prove food-industry revenue or regulatory approval. The public record still lacks third-party compositional testing, independent field-yield data, customer purchase orders, a completed approval pathway, or a disclosed manufacturing partner. The strongest evidence is that the company has advanced from laboratory and greenhouse experiments into outdoor cultivation and industry sampling.

**Founders and team background.** PoLoPo was founded in 2022 by Dr. Maya Sapir-Mir and Dr. Raya Liberman-Aloni, who met during doctoral studies and bring backgrounds in plant metabolism, developmental biology, and agricultural biotechnology. Sapir-Mir is publicly identified as co-founder and CEO, while Liberman-Aloni is co-founder and CTO. The company also identifies Ido Eliashar as vice president of business development and lists advisors covering regulation, industry strategy, intellectual property, U.S. trials, and food supply chains. That division of labor is appropriate for the company's real bottleneck: PoLoPo needs scientific control over plant expression and crop performance, but it also needs regulatory strategy, field-trial execution, extraction, ingredient formulation, and access to food manufacturers. Public profiles describe a very small organization, with LinkedIn listing a 2-10 employee range and Startup Nation Finder reporting a larger 11-50 range; the discrepancy is unresolved, so headcount should not be treated as exact. The scientific founder-market fit is strong for molecular farming, and the advisor roster suggests awareness of commercialization requirements. The remaining diligence question is whether the organization has enough in-house agronomy, process engineering, quality, regulatory, and business-development capacity to run a crop platform and a food-ingredient program simultaneously.

**Competitive dynamics.** PoLoPo competes on several layers. In Israeli molecular farming, Finally Foods develops dairy proteins in engineered potatoes, while Plantopia focuses on casein in engineered plant hosts; both demonstrate that plant-based protein manufacturing is a credible local category, but neither is the same company or lead product. Nobell Foods has pursued plant-made casein, and NewMoo has explored plant-derived dairy proteins, creating competition for food manufacturers interested in avoiding animal agriculture. Precision-fermentation companies such as Remilk, Imagindairy, Perfect Day, and Formo offer alternative routes to animal-identical proteins with more familiar industrial-bioprocess logic. Conventional egg-white, dairy-protein, and potato-protein suppliers remain the practical incumbents because their products, safety files, procurement channels, and production economics are established. PoLoPo's proposed edge is the coupling of a common field crop, tuber-localized protein accumulation, and a processing-compatible snack entry point. The counterargument is equally clear: rival molecular-farming platforms may achieve better yields or simpler regulation, fermentation may scale more predictably, and an incumbent ingredient supplier can compete on price and reliability. Defensibility will depend on patent scope, stable expression across varieties and seasons, extraction economics, customer-specific formulation data, and regulatory approvals rather than on the phrase molecular farming alone.

**Defense, security, and resilience relevance.** PoLoPo's dual-use case is food-system resilience and should be scored as a credible adjacency, not as a defense product. Modern militaries, civil-defense organizations, hospitals, and remote communities all depend on protein ingredients and calorie-dense food supply chains that can be disrupted by animal disease, drought, shipping interruptions, sanctions, or conflict. A crop platform that can produce functional proteins locally through ordinary agricultural infrastructure could diversify supply and reduce dependence on centralized livestock or fermentation capacity. The potato is especially relevant to resilience planning because it is already a widely cultivated staple and can serve as both food and a production host. In an expeditionary or civil-contingency scenario, PoLoPo's technology could support regional production of shelf-stable protein ingredients, high-protein staple foods, or specialized nutrition, subject to biosafety, processing, and regulatory constraints. This is not evidence of military use: PoLoPo has disclosed no defense customer, government procurement program, military trial, classified deployment, or field ration contract. Nor is there public proof that its engineered potatoes can be grown in disrupted environments or that the downstream process is compact enough for distributed production. The strategic value is therefore concentrated in agricultural diversification, protein sovereignty, and resilience of food manufacturing, with defense relevance remaining a future application hypothesis.

**Growth stage, trajectory, and key diligence risks.** PoLoPo is early stage. It has a named scientific platform, identifiable founders, seed financing, public field-cultivation progress, a growing sample-production capability, and a sharper snack-market wedge, but it has not publicly demonstrated mature commercial scale. The trajectory depends on choosing the right sequence of milestones: first reproduce protein content and agronomic performance across multiple potato varieties and seasons; then verify extraction, functionality, safety, and cost; next complete the regulatory work required for engineered crops and food ingredients in target markets; and finally convert brand pilots into repeat agricultural supply and ingredient contracts. The central diligence risks are: (1) biological variability between greenhouse, field, and commercial farms; (2) regulatory delay or rejection for genetically engineered crops and derived food ingredients; (3) yield and purification economics that fail to beat fermentation or conventional proteins; (4) customer concentration if one snack or ingredient partner becomes the only route to revenue; (5) weather, disease, and seed-supply exposure; (6) patent freedom-to-operate and the ability to protect SuperAA beyond a narrow implementation; and (7) public claims such as three-times protein, three-ton field output, and expected approvals that still need independent validation. PoLoPo is a strategically interesting Israeli food-security company, but the next proof point is repeatable, approved, costed product—not another demonstration crop.